Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ (30,143,000)	$ 30,586,000	$ (314,925,000)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	78,716,000	85,362,000	93,807,000
Non-cash interest	9,389,000	9,994,000	8,731,000
Amortization of deferred financing costs	785,000	847,000	995,000
Losses from investments in investees	629,000	480,000	2,900,000
Equity-based compensation – employees and non-employees	13,632,000	8,947,000	13,421,000
Asset impairment charges	0	0	92,399,000
Non-cash revenue from the transfer of intellectual property	(3,801,000)	0	0
Realized loss (gain) on disposal of fixed assets and sales of equity securities	(33,922,000)	(10,681,000)	739,000
Loss on conversion of the 2025 Notes	11,111,000	0	0
Change in fair value of equity securities and derivative instruments	3,967,000	(101,000)	8,748,000
Change in fair value of contingent consideration	(1,703,000)	(3,989,000)	(14,854,000)
Deferred income tax provision	10,159,000	15,640,000	4,324,000
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	5,232,000	(150,437,000)	7,376,000
Inventory, net	30,684,000	(77,642,000)	(12,133,000)
Other current assets and prepaid expenses	1,478,000	20,504,000	(11,486,000)
Other assets	260,000	(447,000)	409,000
Accounts payable	(10,847,000)	37,159,000	15,636,000
Foreign currency measurement	2,345,000	(3,185,000)	(71,000)
Contract liabilities	(15,911,000)	(5,389,000)	(69,302,000)
Accrued expenses and other liabilities	(33,723,000)	81,828,000	764,000
Net cash provided by (used in) operating activities	38,337,000	39,476,000	(172,522,000)
Cash flows from investing activities:
Investments in investees	(2,000,000)	0	(1,200,000)
Proceeds from sale of investments	8,079,000	15,110,000	0
Acquisition of businesses, net of cash acquired	(4,000,000)	0	0
Proceeds from the sale of property, plant and equipment	66,026,000	245,000	671,000
Capital expenditures	(32,156,000)	(33,682,000)	(12,741,000)
Net cash provided by (used in) investing activities	35,949,000	(18,327,000)	(13,270,000)
Cash flows from financing activities:
Issuance of common stock	0	0	76,062,000
Issuance of 2023 Convertible Notes, including to related parties	0	0	200,293,000
Debt issuance costs	(188,000)	0	(7,762,000)
Proceeds from the exercise of common stock options and warrants	1,080,000	756,000	(3,000)
Borrowings on lines of credit	1,684,713,000	1,107,866,000	294,780,000
Repayments of lines of credit	(1,695,956,000)	(1,143,698,000)	(359,322,000)
Redemption of 2033 Senior Notes	0	0	(28,800,000)
Net cash (used in) provided by financing activities	(10,351,000)	(35,076,000)	175,248,000
Effect of exchange rate changes on cash and cash equivalents	(1,436,000)	686,000	(477,000)
Net increase (decrease) in cash and cash equivalents	62,499,000	(13,241,000)	(11,021,000)
Cash and cash equivalents at beginning of period	72,211,000	85,452,000	96,473,000
Cash and cash equivalents at end of period	134,710,000	72,211,000	85,452,000
SUPPLEMENTAL INFORMATION:
Interest paid	8,515,000	10,908,000	11,873,000
Income taxes paid, net of refunds	5,969,000	(903,000)	2,667,000
Operating lease right-of-use assets due to adoption of ASU No. 2016-02	0	0	39,380,000
Operating lease liabilities due to adoption of ASU No. 2016-02	0	0	39,703,000
Operating lease right-of-use assets obtained in exchange for lease obligations	6,493,000	0	0
Non-cash financing:
Shares issued upon the conversion of - Common Stock options and warrants, surrendered in net exercise	$ 0	$ 0	$ 20,000